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Lung cancer is the most frequent cause of cancer deaths. It accounts for 28% of allcancer deaths and 1.3 million deaths globally. In the United States, 216,000 people are
diagnosed with lung cancer every year and only 16% of the patients will survive more than
5 years. Unfortunately, only 15% of patients with lung cancer are diagnosed with
“localized” disease compared to 60%, 80%, and 40% of patients with breast-, prostate-
and colorectal cancers, respectively.1 While significant improvement in prognosis has
occurred in many other solid tumors, little improvement has been seen – so far – in lung
cancer.
A question raised many times is why it there such a slow improvement in lung
cancer compared to many other solid tumors. Lung carcinogenesis is a complicated
process and lung cancer might be more biological heterogeneous than many other tumors.
However, other factors play in. The difference in federal research money devoted to lung
cancer compared to many other cancers seems disproportional to the magnitude of the
health problem lung cancer is representing .The federal research funding (FY10) per death
is for lung cancer $1,386 compared to $28,660 for breast and $13,697 for prostate cancer.1
The NIH (including FY10 stimulus) funding for lung cancer is $203 mill. compared to
$788 million for breast cancer and $345 million for prostate cancer.2
For the lung cancer community, it is important that we get a multidisciplinary
discussion on what are the obstacles for improvements. Recently, an international
multidisciplinary (e.g., surgery, medical oncology, pathology, basic science) workshop
was held, including representatives from the patients’ advocacy groups (sponsored by
GlaxoSmithKline), with the goal of identifying barriers for improvements for early stage
disease.3 Several barriers were clearly identified, including perception of stigma and
nihilism in the public, slow accrual to clinical trials, technical aspects, lack of strict
guidelines for design of clinical trials, and lack of research findings.
Lung cancer is seen as “self-inflicted” because of its association with tobacco. The
general public holds negative and prejudicial attitudes toward lung cancer despite the fact
that nearly 80% of the patients are former- or never smokers.1 In contrast, patients with
heart disease are rarely told their disease is self-inflicted because they are overweight,
sedentary, and ate a poor diet. Patients who have never smoked (18%) are particularly
impacted by “victim-blaming.” Even healthcare professionals often assume they are
smokers or ex-smokers. The poor treatment outcomes with lung cancer have led to a
climate of nihilism about the disease among health care professionals, the public and the
media. There is little media interest in lung cancer because it is seen as depressing. For
example, lung cancer kills more women than breast cancer, yet, in contrast to breast
cancer, it is virtually ignored by the women’s media. The media want positive stories
about cancer, and are interested in young, photogenic patients. Lung cancer cannot
generally supply those stories, so despite its being the most common cancer, the media is
not interested. One approach has been to emphasize women with lung cancer, to show it
is not just a disease of men. We need to publicize the fact that anyone can get lung cancer.
More multidisciplinary discussions needs to take place in order to identify the
barriers for improvements in early- and late-stage disease as well as for successful
screening of lung cancer.
The “Tissue is the Issue” towards successful personalized medicine! The lung
cancer doctors and particularly the patients need to be made aware of the importance of
sufficient tissue acquisition and biomarker assessments for choice of therapy and for
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future research. The proportion of lung cancer patients treated
in clinical trials is lower than in many other cancers, despite
the fact that patients in clinical trials tend to do better. The
importance of participation in well designed prospective
clinical trials needs to be emphasized. Advocacy groups
might help increase recruitment into clinical trials. Better
advertising of trials and better doctor/patient education on the
role of clinical trials and biomarker assessments/research is
crucial. The patients’ education could be done through patient
information leaflets, or as a part of attendance letters sent by
clinics. More resources needs also to be allocated to better
identification of high risk populations and new screening
strategies, which should include biomarker studies in con-
junctions with imaging studies.
Hopefully, the “Awareness Month” will raise aware-
ness of the many needs and barriers for improvements in
lung cancer therapy and reduction of lung cancer specific
mortality.
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